Top brokerages issue ratings and targets for key stocks: Motilal Oswal upgrades HDFC Life to buy; Jefferies reaffirms buy for Sun Pharma; UBS stays neutral on Nykaa; Jefferies advises hold on Jubilant FoodWorks. Analysts anticipate growth trajectories and address performance factors.
Brokerage maintained a buy on , has a rating on , Jefferies recommended a on , and upgraded to buy.We have collated a list of from top brokerage firms from ETNow and other sources:
Motilal Oswal on HDFC Life: Buy| Target Rs 700
Motilal Oswal upgraded to from neutral earlier and also raised the to Rs 700 from Rs 670.
The has corrected by about 20% in the past 5 months. Surrender charges risk is already priced in more than adequately.
Industry premiums are likely to grow by 12-15%, and HDFC Life is likely to grow at the higher end of the range.
The domestic brokerage firm sees FY25 APE at ~15%.
Jefferies on Sun Pharma: Buy| Target Rs 1785
Jefferies maintained a buy rating on Sun Pharma post Q4 results but raised the target price to Rs 1785 from Rs 1585 earlier.
The pharma major reported a miss on consolidated estimates but growth is likely to pick up in FY26.
FY25 guidance was a mixed bag with high single-digit sales growth but a sharp increase in R&D and opex spending.
The global investment bank expects subdued FY25 but growth to rebound from FY26 onwards.
UBS on Nykaa: Neutral| Target Rs 210
UBS maintained a neutral rating on NYKAA post Q4 results with a target price of Rs 210. The company reported an Improved GMV/revenue growth in Q4, but continued lack of operating leverage.
The growth trajectory seen in Q4 should continue into FY25.
Jefferies on Jubilant FoodWorks: Hold| Target Rs 475
Jefferies maintained a hold rating on Jubilant FoodWorks but slashed the target price to Rs 475 from Rs 500 earlier.
The company reported a record low margin, but delivery growth has picked up. It saw some stabilisation in LFL/SSS in Q4. Jubilant transformed from India to one of the largest EM franchises now.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
Source: Stocks-Markets-Economic Times